Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

FDA Approves VivaLnk’s Wearable Device for Continuous Temperature Monitoring

XTALKS VITALS NEWS

The soft and flexible wearable device uses the company’s eSkin technology to collect temperature readings and display them on a connected smartphone or tablet.

Share this!

April 6, 2017 | by Sarah Hand, M.Sc.

Digital health startup, VivaLnk, has just received FDA clearance for their continuous temperature monitoring medical device, Fever Scout. The soft and flexible wearable device uses the company’s eSkin technology to collect temperature readings and display them on a connected smartphone or tablet.

According to VivaLnk, the device is ideal for remote monitoring of a child’s fever. The wearable device will be available for purchase by consumers at stores like Best Buy, Target and Amazon.

“Driving meaningful innovation to help improve people's health and wellbeing is a part of our DNA at VivaLnk. We developed Fever Scout to help take the guesswork out of monitoring and keeping track of a patient's fever,” said Jiang Li, co-founder and CEO of VivaLnk. “Starting today, consumers can now own a wearable thermometer that is an accurate medical grade device, child-friendly and does its job while the patient is sleeping.”



Fever Scout uses Bluetooth to connect to the product’s app on a smartphone or tablet device. The thermometer patch itself can be stuck to the skin using a medical-grade adhesive, and patients can wear the device for up to seven days before the battery will need to be recharged.

The medical device continuously monitors a patient’s temperature and sends alerts to the app whenever the patient’s fever increases. Fever data collected over time can be submitted to a patient’s doctor along with other symptoms and medication schedules, to provide an overall picture of whether the person’s health is improving.

“It's no secret in the medical community that the trouble with consumer wearables is that they are not medical grade devices, and have lacked the accuracy and consistency required for patient care,” said Dr. Vernon Smith, Mayo Clinic-trained emergency physician from Avera Medical Group. “The introduction of Fever Scout signals a future where we can one day accurately use wearables to remotely monitor at-risk patients, like the elderly, by tracking baseline temperatures and anticipating when trouble might arise.”

While the design of the Fever Scout is certainly kid-friendly, its use can benefit patients and caregivers of any age. Patients recovering from surgery or cancer treatment and seniors who live with their primary caregivers could also use the Fever Scout for continuous body temperature monitoring.


Keywords:  FDA, Wearable Device, Remote Patient Monitoring


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.